Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Estimating the variance for heterogeneity in arm‐based network meta‐analysis

View through CrossRef
Network meta‐analysis can be implemented by using arm‐based or contrast‐based models. Here we focus on arm‐based models and fit them using generalized linear mixed model procedures. Full maximum likelihood (ML) estimation leads to biased trial‐by‐treatment interaction variance estimates for heterogeneity. Thus, our objective is to investigate alternative approaches to variance estimation that reduce bias compared with full ML. Specifically, we use penalized quasi‐likelihood/pseudo‐likelihood and hierarchical (h) likelihood approaches. In addition, we consider a novel model modification that yields estimators akin to the residual maximum likelihood estimator for linear mixed models. The proposed methods are compared by simulation, and 2 real datasets are used for illustration. Simulations show that penalized quasi‐likelihood/pseudo‐likelihood and h‐likelihood reduce bias and yield satisfactory coverage rates. Sum‐to‐zero restriction and baseline contrasts for random trial‐by‐treatment interaction effects, as well as a residual ML‐like adjustment, also reduce bias compared with an unconstrained model when ML is used, but coverage rates are not quite as good. Penalized quasi‐likelihood/pseudo‐likelihood and h‐likelihood are therefore recommended.
Title: Estimating the variance for heterogeneity in arm‐based network meta‐analysis
Description:
Network meta‐analysis can be implemented by using arm‐based or contrast‐based models.
Here we focus on arm‐based models and fit them using generalized linear mixed model procedures.
Full maximum likelihood (ML) estimation leads to biased trial‐by‐treatment interaction variance estimates for heterogeneity.
Thus, our objective is to investigate alternative approaches to variance estimation that reduce bias compared with full ML.
Specifically, we use penalized quasi‐likelihood/pseudo‐likelihood and hierarchical (h) likelihood approaches.
In addition, we consider a novel model modification that yields estimators akin to the residual maximum likelihood estimator for linear mixed models.
The proposed methods are compared by simulation, and 2 real datasets are used for illustration.
Simulations show that penalized quasi‐likelihood/pseudo‐likelihood and h‐likelihood reduce bias and yield satisfactory coverage rates.
Sum‐to‐zero restriction and baseline contrasts for random trial‐by‐treatment interaction effects, as well as a residual ML‐like adjustment, also reduce bias compared with an unconstrained model when ML is used, but coverage rates are not quite as good.
Penalized quasi‐likelihood/pseudo‐likelihood and h‐likelihood are therefore recommended.

Related Results

Integrating mean and variance heterogeneities to identify differentially expressed genes
Integrating mean and variance heterogeneities to identify differentially expressed genes
Abstract Background In functional genomics studies, tests on mean heterogeneity have been widely employed to identify dif...
De-escalation of axillary surgery in breast cancer : patient experiences, arm morbidity, and health-related quality of life
De-escalation of axillary surgery in breast cancer : patient experiences, arm morbidity, and health-related quality of life
<p dir="ltr">In breast cancer surgery for node-positive disease, axillary staging surgery is typically performed alongside the tumour removal. Arm morbidity is a known conseq...
De-escalation of axillary surgery in breast cancer : patient experiences, arm morbidity, and health-related quality of life
De-escalation of axillary surgery in breast cancer : patient experiences, arm morbidity, and health-related quality of life
<p dir="ltr">In breast cancer surgery for node-positive disease, axillary staging surgery is typically performed alongside the tumour removal. Arm morbidity is a known conseq...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Abstract Thoracic outlet syndrome (TOS) is a complex and often overlooked condition caused by the compression of neurovascular structures as they pass through the thoracic outlet. ...

Back to Top